Sexual side-effects of antidepressant and antipsychotic drugs

Montejo, Ángel L.; Montejo, Laura; Navarro-Cremades, Felipe

doi:10.1097/yco.0000000000000198

Cited by 143 publications

(64 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, previous studies in depressed female patients revealed a lower prevalence of sexual dysfunctions compared with what we found in our cohort of PD patients — in 100,000 depressed women, 17.7% had hypoactive sexual desire disorder, 3.4% sexual aversion disorder, 5.8% sexual arousal disorder, and 7.7% orgasmic disorder . Almost half of our patients were taking antidepressants, which is also an important aspect, given that some of these drugs, especially serotoninergic ones, may cause sexual side effects, such as decreased libido, arousal difficulties, delayed orgasm, and anorgasmia . Still, only six patients had total BDI scores compatible with moderate to severe depressive symptoms (range 18‐63), four of whom had a previous diagnosis of depression.…”

Section: Discussionsupporting

confidence: 54%

Sexual dysfunction in women with Parkinson's disease

et al. 2016

View full text Add to dashboard Cite

Backgro und: Sexual dysfunction in women with Parkinson's disease is poorly understood and research in this area is scarce. The objectives of this study were sexual function characterization in female Parkinson's disease patients, description of sexual dysfunctions, correlation with disease characteristics, and comparison with matched healthy controls. Methods: Social and demographic data from consecutive female patients with Parkinson's disease and matched healthy controls were collected. The following instruments were used: UPDRS, the Hoehn and Yahr scale, the Beck Depression Inventory-II, the Female Sexual Function Index, and the Sexual Dysfunction Inventory. The only exclusion criterion was cognitive deterioration precluding comprehension of the study scope and its instruments. Results: Of the 95 patients identified, 61 were included. Mean age was 66 years (range 40-89 years), and mean disease duration was seven years (range 1-18 years). Twenty-nine presented an akinetic-rigid syndrome, 25 tremoric disease, and, the remaining, a mixed type of disease. Mean "on" total/part III UPDRS scores were 46 6 15.0 and 31 6 8.9. Sexual dysfunction was present in 86.9% of patients and 79.0% of controls, according to the Female Sexual Function Index (p < .01), and in 57.4% of patients and 22.6% of controls, according to the Sexual Dysfunction Inventory (p < .001). Multivariate binary logistic regression identified age and depressive symptoms as positive predictors in the severity of sexual dysfunction. Disease duration, UPDRS part III score, Hoehn and Yahr stage, and antiparkinsonian medication did not show significant predictive value. Conclusions: Sexual dysfunction is more prevalent in women with Parkinson's disease than in controls and is predicted by older age and severity of depressive symptoms. V C 2016 International Parkinson and Movement Disorder Society

show abstract

Section: Discussionsupporting

confidence: 54%

Sexual dysfunction in women with Parkinson's disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In addition, mirtazapine and agomelatine have been associated with lower risks of sexual side effects [104]. Preliminary data suggest that vortioxetine and vilazodone might have some advantage over SSRIs with regards to sexual side effects [59,60,105]. …”

Section: Sexual Dysfunctionmentioning

confidence: 99%

The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature

Carvalho

Sharma²,

Brunoni³

et al. 2016

Psychother Psychosom

486

357

View full text Add to dashboard Cite

Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later. They encompass gastrointestinal symptoms (nausea, diarrhea, gastric bleeding, dyspepsia), hepatotoxicity, weight gain and metabolic abnormalities, cardiovascular disturbances (heart rate, QT interval prolongation, hypertension, orthostatic hypotension), genitourinary symptoms (urinary retention, incontinence), sexual dysfunction, hyponatremia, osteoporosis and risk of fractures, bleeding, central nervous system disturbances (lowering of seizure threshold, extrapyramidal side effects, cognitive disturbances), sweating, sleep disturbances, affective disturbances (apathy, switches, paradoxical effects), ophthalmic manifestations (glaucoma, cataract) and hyperprolactinemia. At times, such adverse events may persist after drug discontinuation, yielding iatrogenic comorbidity. Other areas of concern involve suicidality, safety in overdose, discontinuation syndromes, risks during pregnancy and breast feeding, as well as risk of malignancies. Thus, the rational selection of ADs should consider the potential benefits and risks, likelihood of responsiveness to the treatment option and vulnerability to adverse events. The findings of this review should alert the physician to carefully review the appropriateness of AD prescription on an individual basis and to consider alternative treatments if available.

show abstract

“…As noted earlier, SSRIs produce a whole host of side effects, while the newer classes of antidepressant that act on NE neurotransmission (i.e., venlafaxine, duloxetine, mirtazapine) have been found to produce fewer side effects (Calabrò, Manuli, Portaro, Naro, & Quattrini, 2018). Taking into account that norepinephrine plays a facilitatory role in regulating human sexual behavior, the balancing of the negative effect of 5-HT on sexuality (by increasing the brain norepinephrine levels) may justify the fact that the newer classes of antidepressant that act on NE neurotransmission have lower sexual dysfunction incidence than SSRI (Behrens, Berg, Jbabdi, Rushworth, & Woolrich, 2007;Clayton, Haddad, Iluonakhamhe, Ponce Martinez, & Schuck, 2014;Hull et al, 2004;Johannessen Landmark, Henning, & Johannessen, 2016;Montejo, Montejo, & Navarro-Cremades, 2015).…”

Section: Norepinephrinementioning

confidence: 99%

Neuroanatomy and function of human sexual behavior: A neglected or unknown issue?

et al. 2019

View full text Add to dashboard Cite

IntroductionSexual desire, arousal, and orgasm are mediated by complex, yet still not fully understood, interactions of the somatic and autonomic nervous systems operating at the central and peripheral levels. Disruption of endocrine, neural, or vascular response, caused by aging, medical illness, neurological diseases, surgery, or drugs, can lead to sexual dysfunctions, thus significantly affecting patients' quality of life.PurposeThis narrative review aims at characterizing the involvement of the central nervous system in human sexual behavior.MethodsA literature search was conducted using PubMed in its entirety up to June 2018, analyzing the studies dealing with the neurobiological and neurophysiological basis of human sexuality.ResultsSexual behavior is regulated by both subcortical structures, such as the hypothalamus, brainstem, and spinal cord, and several cortical brain areas acting as an orchestra to finely adjust this primitive, complex, and versatile behavior. At the central level, dopaminergic and serotonergic systems appear to play a significant role in various factors of sexual response, although adrenergic, cholinergic, and other neuropeptide transmitter systems may contribute as well.ConclusionsProviding healthcare professionals with information concerning sexual behavior may overcome useless and sometimes dangerous barriers and improve patient management, since sexual well‐being is considered one of the most important aspects of one's quality of life.

show abstract

Sexual side-effects of antidepressant and antipsychotic drugs

Cited by 143 publications

References 43 publications

Sexual dysfunction in women with Parkinson's disease

Sexual dysfunction in women with Parkinson's disease

The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature

Neuroanatomy and function of human sexual behavior: A neglected or unknown issue?

Contact Info

Product

Resources

About